[go: up one dir, main page]

EE04796B1 - Fumaarhappe mikrotabletid - Google Patents

Fumaarhappe mikrotabletid

Info

Publication number
EE04796B1
EE04796B1 EEP200100030A EEP200100030A EE04796B1 EE 04796 B1 EE04796 B1 EE 04796B1 EE P200100030 A EEP200100030 A EE P200100030A EE P200100030 A EEP200100030 A EE P200100030A EE 04796 B1 EE04796 B1 EE 04796B1
Authority
EE
Estonia
Prior art keywords
micro
tablets
fumaric acid
cation
series
Prior art date
Application number
EEP200100030A
Other languages
English (en)
Estonian (et)
Inventor
Kumar Joshi Rajendra
Strebel Hans-Peter
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of EE200100030A publication Critical patent/EE200100030A/xx
Publication of EE04796B1 publication Critical patent/EE04796B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Soft Magnetic Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EEP200100030A 1998-10-20 1999-10-08 Fumaarhappe mikrotabletid EE04796B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19848260A DE19848260C2 (de) 1998-10-20 1998-10-20 Fumarsäure-Mikrotabletten
PCT/EP1999/007568 WO2000023068A2 (fr) 1998-10-20 1999-10-08 Microcomprimes d'acide fumarique

Publications (2)

Publication Number Publication Date
EE200100030A EE200100030A (et) 2002-06-17
EE04796B1 true EE04796B1 (et) 2007-04-16

Family

ID=7885018

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100030A EE04796B1 (et) 1998-10-20 1999-10-08 Fumaarhappe mikrotabletid

Country Status (27)

Country Link
US (1) US6355676B1 (fr)
EP (1) EP1123092B1 (fr)
JP (1) JP3550091B2 (fr)
CN (1) CN1235578C (fr)
AT (1) ATE222760T1 (fr)
AU (1) AU745889B2 (fr)
BG (1) BG64836B1 (fr)
BR (1) BR9910267A (fr)
CA (1) CA2329543C (fr)
CZ (1) CZ300005B6 (fr)
DE (2) DE19848260C2 (fr)
DK (1) DK1123092T3 (fr)
EE (1) EE04796B1 (fr)
ES (1) ES2182568T3 (fr)
HK (1) HK1041216B (fr)
HU (1) HU229384B1 (fr)
IL (1) IL140891A (fr)
MX (1) MXPA01003966A (fr)
NO (1) NO328720B1 (fr)
NZ (1) NZ508065A (fr)
PL (1) PL193119B1 (fr)
PT (1) PT1123092E (fr)
RS (1) RS49775B (fr)
RU (1) RU2210366C2 (fr)
SK (1) SK286191B6 (fr)
TR (1) TR200003505T2 (fr)
WO (1) WO2000023068A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
HU230252B1 (hu) 2001-01-12 2015-11-30 Biogen Idec International Gmbh Fumársav-amid származékok
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US6613800B1 (en) * 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
ES2297461T3 (es) * 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
PL2801355T3 (pl) 2004-10-08 2015-10-30 Fwp Ip Aps Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DE602006011910D1 (de) 2005-07-07 2010-03-11 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
EP1915334A2 (fr) * 2005-07-07 2008-04-30 Aditech Pharma AB Nouveaux sels de monoalkylesters d'acide fumarique et leur utilisation pharmaceutique
DE502005010444D1 (de) * 2005-08-19 2010-12-09 Verla Pharm Magnesium-Mikrotabletten mit verzögerter Freisetzung
WO2007042035A2 (fr) * 2005-10-07 2007-04-19 Aditech Pharma Ab Therapie de combinaison pour le traitement d'un trouble auto-immun et/ou inflammatoire et de conditions associees
JP2009510137A (ja) * 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
EP2680010A1 (fr) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Essais de criblage de nrf2 et procédés et compositions correspondants
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
WO2010022177A2 (fr) 2008-08-19 2010-02-25 Xenoport, Inc. Promédicaments de fumarate de méthyle-hydrogène, compositions pharmaceutiques à base de ceux-ci, et procédés d'utilisation
EP2379063B2 (fr) * 2009-01-09 2021-02-24 Fwp Ip Aps Formule pharmaceutique comportant un ou plusieurs esters d'acide fumarique dans une matrice erosive
SI2718257T1 (en) 2011-06-08 2018-04-30 Biogen Ma Inc. PROCEDURE FOR PREPARATION OF HIGH QUALITY CRYSTALINIC DIMETHY OF FUMARAT
WO2013076216A1 (fr) 2011-11-24 2013-05-30 Synthon Bv Libération contrôlée de particules comprenant du diméthylfumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
SG11201404705YA (en) 2012-02-07 2014-10-30 Biogen Idec Inc Pharmaceutical compositions containing dimethyl fumarate
CN104169261A (zh) 2012-02-07 2014-11-26 什诺波特有限公司 富马酸吗啉代烃基酯化合物、药物组合物和使用方法
CA2882713A1 (fr) 2012-08-22 2014-02-27 Xenoport, Inc. Methodes d'administration du monomethyl fumarate et des promedicaments associes presentant des effets secondaires reduits
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US20140171504A1 (en) * 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
ES2733961T3 (es) 2012-12-21 2019-12-03 Biogen Ma Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
NZ741985A (en) 2013-03-14 2019-12-20 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (fr) 2013-03-24 2014-10-02 Xenoport, Inc. Compositions pharmaceutiques de fumarate de diméthyle
WO2014197860A1 (fr) 2013-06-07 2014-12-11 Xenoport, Inc. Procédé de production de monométhylfumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
CN105682648A (zh) 2013-08-26 2016-06-15 前进制药公司 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US20150079180A1 (en) 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
EP3656379A1 (fr) 2013-12-12 2020-05-27 Almirall S.A. Compositions pharmaceutiques contenant du fumarate de diméthyle
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2015130998A1 (fr) 2014-02-28 2015-09-03 Banner Life Sciences Llc Capsules molles entériques à libération contrôlée d'esters de fumarate
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (fr) 2014-10-15 2016-04-21 Xenoport, Inc. Composés de fumarate, compositions pharmaceutiques et procédés d'utilisation
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (fr) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des maladies liées à des dysfonctions mitochondriales
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2020094767A1 (fr) 2018-11-08 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'activateurs de nrf2 pour le traitement d'infections à staphylocoque doré
JP7406566B2 (ja) 2019-04-17 2023-12-27 イクシェル ファーマ エルエルシー フマル酸モノメチルのプロドラッグ
JP7224067B2 (ja) 2019-05-31 2023-02-17 キュラクル カンパニー リミテッド フマル酸ジメチルを含有する腸溶性錠剤
CN110898164A (zh) * 2019-12-19 2020-03-24 赣州安宏环保科技有限公司 根除胃肠病幽门螺杆菌感染的富马酸单乙酯钙盐及其用途
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
KR20220133807A (ko) 2021-03-25 2022-10-05 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
WO2024047248A1 (fr) 2022-09-02 2024-03-07 Institut National de la Santé et de la Recherche Médicale Utilisation d'activateurs de nrf2 pour le traitement de la maladie des petits vaisseaux cérébraux

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE3572440D1 (en) * 1984-06-19 1989-09-28 Basf Ag Gastro-resistant cylindrical pancreatine-microtablets
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE3834794A1 (de) * 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
GB9220137D0 (en) * 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten

Also Published As

Publication number Publication date
BR9910267A (pt) 2001-01-09
BG104836A (en) 2001-04-30
NZ508065A (en) 2003-08-29
EP1123092B1 (fr) 2002-08-28
HUP0103999A2 (hu) 2002-02-28
DE59902490D1 (de) 2002-10-02
SK5392001A3 (en) 2001-08-06
CZ2001871A3 (cs) 2001-07-11
NO328720B1 (no) 2010-05-03
WO2000023068A3 (fr) 2000-07-27
NO20005239D0 (no) 2000-10-18
NO20005239L (no) 2001-05-21
HK1041216B (zh) 2006-06-30
CN1323206A (zh) 2001-11-21
IL140891A0 (en) 2002-02-10
BG64836B1 (bg) 2006-06-30
WO2000023068A2 (fr) 2000-04-27
RS49775B (sr) 2008-06-05
YU65500A (sh) 2002-09-19
RU2210366C2 (ru) 2003-08-20
TR200003505T2 (tr) 2001-07-23
MXPA01003966A (es) 2002-08-20
CN1235578C (zh) 2006-01-11
IL140891A (en) 2005-09-25
ES2182568T3 (es) 2003-03-01
US6355676B1 (en) 2002-03-12
JP3550091B2 (ja) 2004-08-04
DK1123092T3 (da) 2002-10-14
CA2329543A1 (fr) 2000-04-27
CA2329543C (fr) 2007-02-06
EP1123092A2 (fr) 2001-08-16
HK1041216A1 (en) 2002-07-05
EE200100030A (et) 2002-06-17
DE19848260C2 (de) 2002-01-17
DE19848260A1 (de) 2000-05-18
SK286191B6 (sk) 2008-05-06
HU229384B1 (en) 2013-11-28
ATE222760T1 (de) 2002-09-15
JP2002527475A (ja) 2002-08-27
CZ300005B6 (cs) 2009-01-14
HUP0103999A3 (en) 2003-11-28
PL193119B1 (pl) 2007-01-31
AU6090699A (en) 2000-05-08
PL344528A1 (en) 2001-11-05
PT1123092E (pt) 2003-01-31
AU745889B2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
DK1123092T3 (da) Fumarsyre-mikrotabletter
EE200000440A (et) Fumaarhappe derivaatide kasutamine
IL132819A0 (en) Use of fumaric acid derivatives
IL110089A (en) Sulphonylaminopyrimidines their preparation and pharmaceutical compositions containing them
NZ221424A (en) Pharmaceutical compositions contaipyrimidines
ZA817696B (en) N-substituted omega-(2-oxo-4-imidazolin-1-yl)alcanoic acids,salts and esters thereof,process for producing the same and these active agents containing pharmaceutical compounds
NZ212768A (en) 2-substituted-1,3-propylidene diphosphonate derivatives and pharmaceutical compositions
HUT52374A (en) Process for producing pharmaceutical compositions
IL75852A (en) Pharmaceutical composition containing pyrimido-pyrimidines and o-acetylsalicyclic acid or its pharmacologically tolerated salts
DE69100954D1 (de) Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung.
ZA853715B (en) 3,17 beta-estriol diesters,processes for their production,and pharmaceutical preparations containing them
ATE23800T1 (de) Roentgen-sichtbarmachungsmittel.
IL88011A0 (en) Pharmaceutical preparation for the treatment of psoriasis,psoriatic arthritis,neurodermatitis and enteritis regionalis crohn comprising fumaric acid salts
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.

Legal Events

Date Code Title Description
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner
HD1A Correction of address
MM4A Lapsed by not paying the annual fees

Effective date: 20161008